A Team Approach to ADCs in Bladder Cancer
About this episode
This episode discusses the multidisciplinary approach to treating bladder cancer at UCSF, focusing on the management of antibody-drug conjugates and patient outcomes.
At the University of California, San Francisco (UCSF), the team treating patients with bladder cancer and other genitourinary malignancies utilizes a multidisciplinary team approach to ensure care is coordinated, personalized, and patient-centered. This is particularly important when administering antibody-drug conjugates, a promising tool for some patients with muscle-invasive bladder cancer that comes with a high risk of adverse events (AEs). In this episode, CANCER BUZZ speaks with Terence Friedlander, MD, and Iva Petrovchich Colón, NP, both part of the team treating bladder cancer at UCSF, about how their cancer program manages the toxicity profile of ADCs in order to prioritize patient outcomes and quality of life. Guests: Terence Friedlander, MD Robert and Virginia O'Reilly Family Professor of Medicine Chief of Hematology-Oncology, Zuckerberg San Francisco General Hospital UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, CA Iva Colón, NP Nurse Practitioner, Genitourinary Medical Oncology UCSF Health Genitourinary Medical Oncology Mission Bay San Francisco, CA "The median onset is in the mid 60s, and folks who are in their 60s are more mature, they may…
More episodes of CANCER BUZZ
- The Urology-Oncology Partnership in ADCs
- MDS: Low Risk Isn't No Risk
- Beyond Body Art: Restoring Wholeness Through Paramedical Tattooing
- Bridging Radiation and Oncology in SCLC Care
- Championing Bispecific Antibodies in the VA
- Data-Driven Toxicity Management for ADCs
Explore listener stats, chart rankings, contacts and more on the CANCER BUZZ podcast page.